Nxera Pharma's QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia

Tokyo, Japan and Cambridge, UK, 14 April 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Holling Bio-Pharma Corp. (“Holling”), a leading pharmaceutical distribution and commercialization company based in Taipei, Taiwan, has received approval from the Taiwan Food and Drug Administration (“TFDA”) to market and sell QUVIVIQ® (daridorexant, marketed in Taiwan under the product name 科唯可® film-coated tablets) 25 and 50 mg for the treatment of adults with insomnia. Plans are underway to launch QUVIVIQ® in Taiwan during 2026.